# RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies

> **NCT00529438** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 47 (actual)

## Conditions studied

- Advanced Solid Tumors
- Lymphoid Malignancies

## Interventions

- **DRUG:** Bardoxolone methyl

## Key facts

- **NCT ID:** NCT00529438
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-30
- **Primary completion:** 2008-12-01
- **Final completion:** 2008-12-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529438, "RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00529438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*